Candel Therapeutics, Inc. (CADL)Healthcare | Biotechnology | Needham, United States | NasdaqGM
6.37 USD
+1.21
(23.450%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 6.41 +0.04 (0.609%) ⇧ (April 17, 2026, 7:58 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:58 a.m. EDT
CADL is a raw speculation play on a biotech company nearing breakeven but fundamentally broken with no dividend and massive short interest; while the options market is aggressively betting on an upside push to the $7+ strikes by mid-2026, the lack of solid fundamentals and negative earnings forecasts make this a high-risk instrument suitable only for asymmetric risk-tolerance. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.160289 |
| AutoARIMA | 0.165721 |
| MSTL | 0.171841 |
| AutoTheta | 0.199307 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 48% |
| H-stat | 5.04 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.160 |
| Excess Kurtosis | -0.59 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 94.438 |
| Market Cap | 466,582,912 |
| Forward P/E | -9.95 |
| Beta | -0.81 |
| Website | https://www.candeltx.com |
As of April 19, 2026, 12:58 a.m. EDT: Option market is heavily skewed towards bullish positioning for moderate-term expirations (May and July), with significant new volume flow into ATM calls (6.0) and OTM calls (7.0) in the May 15th session. Call Open Interest at 7.0 is a new top-OI strike for July. Conversely, Put volume is concentrated downside (4.0 and 5.0) but lacks open interest buildup compared to calls, suggesting more stop-selling or short-covering than pure bearish positioning. The yield curve is steep for calls, indicating an expectation of rise with low IV, while puts carry higher IV primarily near expiration due to near-term gamma risk.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.41241682 |
| Address1 | 117 Kendrick Street |
| Address2 | Suite 450 |
| All Time High | 14.78 |
| All Time Low | 0.66 |
| Ask | 6.39 |
| Ask Size | 4 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 1,336,160 |
| Average Daily Volume3 Month | 1,214,345 |
| Average Volume | 1,214,345 |
| Average Volume10Days | 1,336,160 |
| Beta | -0.807 |
| Bid | 6.35 |
| Bid Size | 12 |
| Board Risk | 5 |
| Book Value | 0.946 |
| City | Needham |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.37 |
| Current Ratio | 13.492 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 6.45 |
| Day Low | 5.2301 |
| Debt To Equity | 94.438 |
| Display Name | Candel Therapeutics |
| Earnings Timestamp | 1,773,318,600 |
| Earnings Timestamp End | 1,778,589,000 |
| Earnings Timestamp Start | 1,778,589,000 |
| Ebitda | -47,331,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -8.364 |
| Enterprise Value | 395,885,920 |
| Eps Current Year | -0.77 |
| Eps Forward | -0.64 |
| Eps Trailing Twelve Months | -0.72 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 5.1501 |
| Fifty Day Average Change | 1.2198997 |
| Fifty Day Average Change Percent | 0.23686911 |
| Fifty Two Week Change Percent | 41.24168 |
| Fifty Two Week High | 7.25 |
| Fifty Two Week High Change | -0.8800001 |
| Fifty Two Week High Change Percent | -0.12137932 |
| Fifty Two Week Low | 4.338 |
| Fifty Two Week Low Change | 2.032 |
| Fifty Two Week Low Change Percent | 0.46841866 |
| Fifty Two Week Range | 4.338 - 7.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,392,600,000 |
| Float Shares | 63,310,981 |
| Forward Eps | -0.64 |
| Forward P E | -9.953125 |
| Free Cashflow | -46,023,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 55 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15797 |
| Held Percent Institutions | 0.32819 |
| Implied Shares Outstanding | 73,246,928 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-27 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts. |
| Long Name | Candel Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 466,582,912 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_37378731 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -38,182,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 467,315,394 |
| Number Of Analyst Opinions | 8 |
| Open | 5.25 |
| Operating Cashflow | -38,311,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 916 5445 |
| Post Market Change | 0.03880024 |
| Post Market Change Percent | 0.6091089 |
| Post Market Price | 6.4088 |
| Post Market Time | 1,776,470,334 |
| Previous Close | 5.16 |
| Price Eps Current Year | -8.272727 |
| Price Hint | 2 |
| Price To Book | 6.7336154 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.308 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 1.21 |
| Regular Market Change Percent | 23.4496 |
| Regular Market Day High | 6.45 |
| Regular Market Day Low | 5.2301 |
| Regular Market Day Range | 5.2301 - 6.45 |
| Regular Market Open | 5.25 |
| Regular Market Previous Close | 5.16 |
| Regular Market Price | 6.37 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 4,126,475 |
| Return On Assets | -0.2595 |
| Return On Equity | -0.64579004 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 73,246,927 |
| Shares Percent Shares Out | 0.2023 |
| Shares Short | 14,816,272 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 12,985,515 |
| Short Name | Candel Therapeutics, Inc. |
| Short Percent Of Float | 0.23969999 |
| Short Ratio | 11.58 |
| Source Interval | 15 |
| State | MA |
| Symbol | CADL |
| Target High Price | 26.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 18.875 |
| Target Median Price | 19.5 |
| Total Cash | 119,731,000 |
| Total Cash Per Share | 1.635 |
| Total Debt | 49,034,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.72 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.511925 |
| Two Hundred Day Average Change | 0.85807467 |
| Two Hundred Day Average Change Percent | 0.15567604 |
| Type Disp | Equity |
| Volume | 4,126,475 |
| Website | https://www.candeltx.com |
| Zip | 2,494 |